Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • Resource and Technical Advances
    • Clinical Medicine
    • Reviews
    • Editorials
    • Perspectives
    • Top read articles
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Concise Communication
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
Inducible podocyte-specific deletion of CTCF drives progressive kidney disease and bone abnormalities
Marta Christov, … , Astrid Weins, Anna Greka
Marta Christov, … , Astrid Weins, Anna Greka
Published February 22, 2018
Citation Information: JCI Insight. 2018;3(4):e95091. https://doi.org/10.1172/jci.insight.95091.
View: Text | PDF
Research Article Endocrinology Nephrology

Inducible podocyte-specific deletion of CTCF drives progressive kidney disease and bone abnormalities

  • Text
  • PDF
Abstract

Progressive chronic kidney diseases (CKDs) are on the rise worldwide. However, the sequence of events resulting in CKD progression remain poorly understood. Animal models of CKD exploring these issues are confounded by systemic toxicities or surgical interventions to acutely induce kidney injury. Here we report the generation of a CKD mouse model through the inducible podocyte-specific ablation of an essential endogenous molecule, the chromatin structure regulator CCCTC-binding factor (CTCF), which leads to rapid podocyte loss (iCTCFpod–/–). As a consequence, iCTCFpod–/– mice develop severe progressive albuminuria, hyperlipidemia, hypoalbuminemia, and impairment of renal function, and die within 8–10 weeks. CKD progression in iCTCFpod–/– mice leads to high serum phosphate and elevations in fibroblast growth factor 23 (FGF23) and parathyroid hormone that rapidly cause bone mineralization defects, increased bone resorption, and bone loss. Dissection of the timeline leading to glomerular pathology in this CKD model led to the surprising observation that podocyte ablation and the resulting glomerular filter destruction is sufficient to drive progressive CKD and osteodystrophy in the absence of interstitial fibrosis. This work introduces an animal model with significant advantages for the study of CKD progression, and it highlights the need for podocyte-protective strategies for future kidney therapeutics.

Authors

Marta Christov, Abbe R. Clark, Braden Corbin, Samy Hakroush, Eugene P. Rhee, Hiroaki Saito, Dan Brooks, Eric Hesse, Mary Bouxsein, Niels Galjart, Ji Yong Jung, Peter Mundel, Harald Jüppner, Astrid Weins, Anna Greka

×

Figure 6

Bone histomorphometry reveals bone loss, osteomalacia, and increased resorption of iCTCFpod–/– mice.

Options: View larger image (or click on image) Download as PowerPoint
Bone histomorphometry reveals bone loss, osteomalacia, and increased res...
(A) Sagittal images generated by μCT imaging of the distal femur of WT (left) and iCTCFpod–/– (right) mice that were sacrificed 8 weeks after Cre induction reveal bone loss. Scale bars: 1 mm. (B) von Kossa staining of tibias of the same WT and iCTCFpod–/– mice reveal osteomalacia and bone loss. Arrows show unmineralized matrix. Scale bars: 20 μm.

Copyright © 2023 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts